ArticleFrontiers in oncology2022
Pancreatic cancer derived 3D organoids as a clinical tool to evaluate the treatment response.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Organoids in Precision Radiotherapy: Methodological Foundations, Tumor-Specific Evidence, and Translational Roadmaps.Cancer medicine · 2026Review
- Tumor organoids modeling reveals timed responses and interplay of radiotherapy and chemotherapy in pancreatic cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026Article
- Radiotherapy in the management of PDAC, from past to present.Translational oncology · 2026Review
- Exploring the landscape of current in vitro and in vivo models and their relevance for targeted radionuclide theranostics.European journal of nuclear medicine and molecular imaging · 2025Review
- Organoid-based precision medicine in pancreatic cancer.United European gastroenterology journal · 2025Review
- Mouse pancreatic tumor organoids reveal synergistic efficacy of low-dose anticancer drug and radiation combinations.Frontiers in medicine · 2025Article
- Radiation response assessment of organoids derived from patients with pancreatic cancer.Clinical and translational radiation oncology · 2024Article
- SOX2 and OCT4 mediate radiation and drug resistance in pancreatic tumor organoids.Cell death discovery · 2024Article
- Multimodal Imaging of Pancreatic Cancer Microenvironment in Response to an Antiglycolytic Drug.Advanced healthcare materials · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Pancreatic cancer (PC) is the fourth leading cause of cancer death in both men and women. The standard of care for patients with locally advanced PC of chemotherapy, stereotactic radiotherapy (RT), or chemo-radiation-therapy has shown highly variable and limited success rates. However, three-dimensional (3D) Pancreatic tumor organoids (PTOs) have shown promise to study tumor response to drugs, and emerging treatments under Methods: PTOs were created from mouse pancreatic tumor tissues, and their microenvironment was compared to that of Results: Pancreatic tumor organoids (PTOs) exhibited a similar fibrotic microenvironment and molecular response (as seen by apoptosis biomarker expression) as Conclusions: PTOs produced a similar microenvironment and exhibited similar growth characteristics as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.